Cell:全新类鸦片止痛药有望问世,效果堪比吗啡,芬太尼,却没有成瘾风险!

2017-11-17 Heather_z727 来宝网

来自斯克里普斯研究所的科学家们开发出新的阿片类止痛药,这种新型止痛药减轻疼痛的能力与吗啡相当,但是药物过量的副作用和风险却大大降低。

新止痛药减少药物过量的风险】来自斯克里普斯研究所的科学家们开发出新的阿片类止痛药,这种新型止痛药减轻疼痛的能力与吗啡相当,但是药物过量的副作用和风险却大大降低。

今天发表在《细胞》杂志上文章描述了一个方法,可以安全使用阿片类止痛药。根据美国疾病控制和预防中心的数据,每天有91人死于阿片类过量,其中包括海洛因,芬太尼等减缓疼痛的药物,也最终停止了人的呼吸。

在此次研究中,研究人员发现一系列的化合物可以达到止痛的效果,却不影响人的呼吸,研究建立在两个几十年的研究中,研究人员长期质疑止痛通路,G蛋白通路,它可以链接的呼吸抑制通路,其中一个问题一直困扰着研究人员,那就是如何分离通道。

在这项研究中,研究人员开发出新的潜在药物分子,然后他们调整化学结构,系统地变化蛋白质信号之间的通路,在过去的六年里,研究人员已经开发了超过500种化合物,他们发现60多信号之间的偏差,接着,他们锁定6个化合物,确定他们在治疗小鼠镇痛和呼吸抑制中的作用。

研究人员发现,这些新的化合物的确可能进入大脑,而所有的化合物都是有效的,所以止痛效果不会低于吗啡,但是与此同时,新的化合物却不太能够诱发小鼠的呼吸抑制。

简而言之,这种新的化合物大大降低了阿片类药物药物过量致死的风险。

原始出处:

Cullen L. Schmid, Nicole M. Kennedy, Nicolette C. Ross, et al. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell, 2017.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2018-01-05 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 1e127dd4m40(暂无匿称)

    期待

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 showtest
  6. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 xue8602
  7. [GetPortalCommentsPageByObjectIdResponse(id=1870287, encodeId=9b7c18e0287b1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 29 08:34:00 CST 2017, time=2017-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960551, encodeId=d5751960551c0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jan 05 13:34:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262502, encodeId=f50026250276, content=期待, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Sun Nov 19 09:33:25 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289979, encodeId=2e5912899e963, content=<a href='/topic/show?id=50e36316e7d' target=_blank style='color:#2F92EE;'>#止痛药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63167, encryptionId=50e36316e7d, topicName=止痛药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346540, encodeId=ce931346540d8, content=<a href='/topic/show?id=2013391531d' target=_blank style='color:#2F92EE;'>#吗啡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39153, encryptionId=2013391531d, topicName=吗啡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384806, encodeId=88fa13848069b, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405543, encodeId=7138140554319, content=<a href='/topic/show?id=597b631634d' target=_blank style='color:#2F92EE;'>#止痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63163, encryptionId=597b631634d, topicName=止痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8da42553722, createdName=zhangxingru, createdTime=Sun Nov 19 02:34:00 CST 2017, time=2017-11-19, status=1, ipAttribution=)]
    2017-11-19 zhangxingru

相关资讯

J CLIN INVEST :科学家发现新药可逆转糖尿病眼病!

对于数以百万计的美国人来说,他们的世界正在溶化成一个无法辨认的模糊视野。糖尿病性视网膜病是一种眼病,影响了3000万(与糖尿病斗争的三分之一人)美国人。随着患者的视力逐渐消失,它永远不会恢复,很少有治疗方法。

Diabetes Obes Metab:3个月减掉5kg!这款糖尿病新药用来减肥也是牛了

一个款即将上市的糖尿病重磅新药或许还将成为肥胖人群的“福利”!发表在Diabetes, Obesity and Metabolism杂志上的一项研究证实,平均来说,在接受了每周一次的该药物治疗后,参与者体重显著下降,12周内减掉了5千克。

Sci Trans Med:乙肝新药进入临床阶段,有望彻底治愈乙肝

德州生物医学研究所西南国家灵长类动物研究中心(SNPRC)的研究人员们开始了慢性乙型肝炎病毒(HBV)新药的临床试验。测试结果显示,这种新颖的治疗方法和药物传递机制是安全有效的,研究结果发表在《国际科学转化医学》杂志上。

FDA宣布将“扩大获取计划”扩展至罕见病患者

一项旨在挽救晚期肿瘤患者的同情用药计划,如今罕见病患者也可以适用。

J Gastroen Hepatol:新药雷莫芦单抗(Ramucirumab)治疗晚期胃癌有奇效!

近日,发表于《胃肠病学和肝脏病学杂志》上的一项最新研究表明,雷莫芦单抗(Ramucirumab)治疗晚期胃癌安全有效。

BJP:这一新型抗抑郁药的出现将给抑郁症治疗带来变革!

巴斯大学的科学家们开发了一种具有独特作用机制的潜在新型抗抑郁和抗焦虑药物。